Online citations, reference lists, and bibliographies.
← Back to Search

Phase I To II Study Of Pleurectomy/decortication And Intraoperative Intracavitary Hyperthermic Cisplatin Lavage For Mesothelioma.

W. Richards, L. Zellos, R. Bueno, M. Jaklitsch, P. Jänne, L. Chirieac, B. Yeap, R. Dekkers, P. M. Hartigan, Leah Capalbo, D. Sugarbaker
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To evaluate morbidity, mortality, maximum-tolerated dose (MTD), and outcome of intraoperative intracavitary hyperthermic cisplatin lavage in patients undergoing pleurectomy for malignant pleural mesothelioma (MPM). PATIENTS AND METHODS Sixty-one patients were prospectively registered. Forty-four resectable patients with MPM underwent pleurectomy, followed by a 1-hour lavage of the resection cavity with dose-escalated cisplatin (50, 100, 150, 175, 200, 225, and 250 mg/m2) at 42 degrees C and then intravenous sodium thiosulfate (16 g/m2 over 6 hours). Survival estimates were compared using the log-rank test and proportional hazards regression. RESULTS Median age was 71 years (range, 50 to 82 years). Twenty-four patients had epithelial tumors, and 20 had sarcomatous or mixed histology. Postoperative mortality was 11% (five of 44 patients). Dose-limiting renal toxicity occurred at 250 mg/m2, establishing the MTD at 225 mg/m2. Other morbidity included atrial fibrillation (14 of 44 patients, 32%) and deep venous thrombosis (four of 44 patients, 9%). Median survival time of all registered patients was 9 months, and the median survival time of resected patients was 13 months. Survival estimates differed significantly for resectable patients exposed to low doses (50 to 150 mg/m2; n = 9; median, 6 months) versus high doses (175 to 250 mg/m2; n = 35; median, 18 months) of hyperthermic cisplatin (P = .0019); recurrence-free interval also differed significantly (4 v 9 months, respectively; P < .0001). Low dose level (relative risk = 3.418) and nonepithelial histology (relative risk = 2.336) were independent risk factors for poor survival. Twenty patients with epithelial tumors who underwent high-dose cisplatin lavage had a 26-month median survival time. CONCLUSION Pleurectomy and high-dose intraoperative intracavitary hyperthermic cisplatin lavage is feasible in this patient population with restricted surgical options. An apparent dose-related survival benefit warrants further study.
This paper references
10.1053/SONC.2002.30236
Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience.
P. Sugarbaker (2002)
10.1080/026567399285738
The effects of intentional hyperthermia on the Thrombelastograph and the Sonoclot analyser.
E. Pivalizza (1999)
10.1016/0277-5379(85)90285-8
Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection.
M. Markman (1985)
10.1159/000227208
A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report.
P. Y. Carry (1993)
10.3109/02656739609023687
Effects of hyperthermal stress on the fibrinolytic system.
K. Tamura (1996)
10.1200/JCO.1983.1.11.695
Malignant mesothelioma following radiation exposure.
K. H. Antman (1983)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1016/S1010-7940(96)01008-1
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.
O. Soysal (1997)
Activation of circulating platelets by hyperthermal stress.
H. Take (1996)
10.1016/0003-4975(92)90654-M
Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
D. Sugarbaker (1992)
10.1200/JCO.2005.00.802
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
C. Lu (2005)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1002/JSO.1143
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
10.1002/1097-0142(19891001)64:7<1422::AID-CNCR2820640710>3.0.CO;2-T
Development of postoperative intrathoracic chemo‐thermotherapy for lung cancer with objective of improving local cure
K. Kodama (1989)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.
S. Howell (1980)
10.1053/EJSO.2000.0978
Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
N. van der Vange (2000)
10.1016/S1010-7940(01)00995-2
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
A. Martin-Ucar (2001)
10.1177/030089169608200111
Surgery Followed by Intracavitary plus Systemic Chemotherapy in Malignant Pleural Mesothelioma
M. Colleoni (1996)
10.1016/S0022-5223(99)70297-7
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
G. B. Ratto (1999)
10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U
Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis.
P. Sugarbaker (1998)
10.1016/0003-4975(94)00614-D
Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion.
Y. Matsuzaki (1995)
10.1016/S0003-3944(00)00253-4
Carcinoses péritonéales traitées par chirurgie de réduction tumorale et chimiohyperthermie intrapéritonéale
Y. Rey (2000)
10.1002/JSO.2930600410
Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The ucla experience
J. D. Lee (1995)
10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
D. Elias (2001)



This paper is referenced by
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1007/s00104-013-2518-8
Regionale Versorgung des malignen Pleuramesothelioms
M. Ried (2013)
10.1016/j.amjsurg.2017.02.003
The seven attributes of the academic surgeon: Critical aspects of the archetype and contributions to the surgical community.
T. Rosengart (2017)
10.1007/s11864-008-0070-4
Diagnosis, Staging, and Surgical Treatment of Malignant Pleural Mesothelioma
M. Kent (2008)
10.1055/A-0934-7806
Expertenempfehlung zur Anwendung der hyperthermen intrathorakalen Chemotherapie (HITOC) in Deutschland
Michael Ried (2020)
Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Y. Matsuzaki (2008)
10.1007/s11864-011-0154-4
Surgical Treatment of Malignant Pleural Mesothelioma
A. Kaufman (2011)
10.1016/j.anndiagpath.2008.11.001
Surgery for malignant pleural mesothelioma.
D. Rice (2009)
10.13032/TJOP.2052-5931.100120
The Role of Surgery in Malignant Pleural Mesothelioma
Levon Toufektzian (2015)
10.2165/00003495-200767080-00005
Management Options for Malignant Pleural Mesothelioma
Ranjit K. Goudar (2012)
STRATEGIES TO ENHANCE EFFICACY OF ONCOLYTIC VIROTHERAPY
S. Pesonen (2016)
10.3389/fphar.2018.01058
Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
X. Yang (2018)
10.1016/j.lungcan.2014.01.021
Surgery for malignant pleural mesothelioma: why, when and what?
L. Lang-Lazdunski (2014)
10.1007/s00104-012-2433-4
Intraoperative Chemotherapie nach radikaler Pleurektomie oder extrapleuraler Pneumonektomie
M. Ried (2012)
10.1007/s00104-019-0989-y
Hypertherme intrathorakale Chemotherapie in der Thoraxchirurgie
H. Hofmann (2019)
10.5761/ATCS.OA.10.01572
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
10.1007/978-1-4471-6404-3_51
Surgical and Medical Therapy for Malignant Pleural Mesothelioma
C. Cao (2014)
10.1016/S1241-8226(12)50101-5
Traitement chirurgical du mésothéliome pleural
Nicolas Vénissac (2012)
10.1007/s00508-016-1036-3
Management of malignant pleural mesothelioma—part 2: therapeutic approaches
M. A. Hoda (2016)
Hyperthermic intrathoracic chemotherapy (HITHOC) in ovarian carcinoma - a propos of a case.
D. Stojiljković (2018)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1007/s00280-007-0500-1
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
G. Gordon (2007)
10.3978/j.issn.2225-319X.2012.11.05
Standardizing surgical treatment in malignant pleural mesothelioma.
D. Rice (2012)
10.1097/ACO.0b013e3282f2a9c3
Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma
Ju-Mei Ng (2008)
10.21037/atm.2017.03.78
Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.
K. Okabe (2017)
10.1177/0218492312454017
Changes in lung function after surgery for mesothelioma
T. Ploenes (2013)
10.2217/fon.14.256
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience.
M. Migliore (2015)
10.1053/j.semtcvs.2008.11.002
Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.
A. Mujoomdar (2008)
10.1016/B978-1-4160-5225-8.00046-5
Innovative Therapy and Technology
Joseph J. Wizorek (2010)
10.21037/shc.2018.06.06
Induction or adjuvant chemotherapy for radical multimodality therapy
Annabel J Sharkey (2018)
10.5580/260
Alternative Options in the Management of Malignant Pleural Mesothelioma
S. Neragi-Miandoab (2007)
10.1016/j.thorsurg.2012.10.002
Surgical management of malignant pleural mesothelioma.
J. Yanagawa (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar